CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
03 October 2018 - 11:00PM
Business Wire
CENTOGENE to conduct a targeted global
identification and recruitment campaign to support Denali´s LRRK2
inhibitor program
CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced
a strategic collaboration for the global identification and
recruitment of LRRK2 mutation carrier Parkinson’s disease (“PD”)
patients.
CENTOGENE will conduct a targeted global recruitment campaign
focused on the early identification and characterization of LRRK2
PD patients and sequence the LRRK2 gene in these patients. Under
the terms of the agreement, CENTOGENE will utilize CentoCard®, its
proprietary, validated, dried blood spot collection kit, to
identify PD patients with a mutation in the LRRK2 gene for
recruitment into Denali’s clinical trials.
Mutations in the LRRK2 gene are one of the most commonly known
genetic causes of Parkinson’s disease and a driver of lysosomal
dysfunction, which contributes to the formation of Lewy body
protein aggregates and neurodegeneration.
“Our exclusive collaboration underscores CENTOGENE’s strong
capability to accelerate the early identification of patients with
rare genetic diseases worldwide. As a leader in providing genetic
insights in rare diseases, we believe we can contribute to Denali’s
development of disease modifying medicines for patients with
Parkinson’s disease. CENTOGENE will help Denali speed up the
enrollment of patients in clinical studies for its LRRK2 program,”
said Dr. Arndt Rolfs, CEO and founder of CENTOGENE.
“Denali is the first company to conduct clinical trials with
LRRK2 inhibitors for the treatment of Parkinson’s disease. This
partnership with CENTOGENE is a central part of our global efforts
to identify and recruit PD patients with a mutation in the LRRK2
gene into our planned clinical studies,” said Carole Ho, M.D.,
Chief Medical Officer and Head of Development at Denali. “We are
impressed with CENTOGENE’s approach and technology and believe that
our joint efforts will accelerate the enrollment of PD patients and
the completion of our clinical trials.”
About CENTOGENE
CENTOGENE unlocks the power of genetic insights to improve the
quality of life of patients with genetic diseases. CENTOGENE
achieves this through knowledge created by its worldwide diagnostic
testing services incorporating global diversity, the world’s
leading proprietary human genetic interpretation database, CentoMD®
and solutions for pharmaceutical companies developing life-changing
orphan drugs. As one of the largest genetic testing companies
worldwide, CENTOGENE is dedicated to transforming the science of
genetic information into solutions and hope for patients with rare
diseases and their families. www.centogene.com; www.centoMD.com
About Denali Therapeutics
Denali is a biopharmaceutical company developing a broad
portfolio of product candidates for neurodegenerative
diseases. Denali pursues new treatments by rigorously
assessing genetically validated targets, engineering delivery
across the blood-brain barrier and guiding development with
biomarker monitoring to demonstrate target engagement and
select patients. Denali is based in South San Francisco.
For additional information, please
visit www.denalitherapeutics.com
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements expressed or implied in this press
release include, but are not limited to, plans for CENTOGENE to
conduct a targeted global recruitment campaign focused on the early
identification and characterization of LRRK2 Parkinson’s disease
patients, the results of utilizing CentoCard® to collect patient
samples to identify patients with a mutation in the LRRK2 gene for
recruitment into Denali clinical trials, CENTOGENE’s ability to
enable Denali to speed up the enrollment of patients in clinical
studies for its LRRK2 program, statements made by CENTOGENE’s CEO
and founder, and statements made by Denali’s Chief Medical Officer
and Head of Development.
Actual results are subject to risks and uncertainties and may
differ materially from those indicated by these forward-looking
statements as a result of these risks and uncertainties, including
but not limited to, risks related to: the risk of the occurrence of
any event, change or other circumstance that could give rise to the
termination of the agreement; Denali’s early stage of clinical drug
development; Denali’s ability to conduct or complete clinical
trials on expected timelines; Denali’s ability to enroll patients
into its clinical trials; and other risks, including those
described in Denali’s Annual Report on Form 10-K filed with the SEC
on March 19, 2018, Denali’s Quarterly Report on Form 10-Q filed
with the SEC on August 9, 2018 and Denali’s future reports to be
filed with the SEC. The forward-looking statements in this press
release are based on information available to Denali as of the
date hereof. Denali disclaims any obligation to update any
forward-looking statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181003005189/en/
CENTOGENE:Doreen Niemann, +49 381
80113510doreen.niemann@centogene.comorMedia
Contact:MacDougall Biomedical CommunicationsLauren Arnold, +1
781-235-3060larnold@macbiocom.comorDenali Therapeutics
Inc.:Lizzie Hyland, +1 646-495-2706lhyland@gpg.comorMorgan
Warners, +1 202-295-0124mwarners@gpg.com
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jul 2023 to Jul 2024